A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

To be part of this study, you need to be at least 18 years old and have been diagnosed with high cholesterol or a mix of unhealthy blood fats by your doctor. You must also be considered at high or very high risk for heart problems.

This study is for people who have recently started taking the specific combination of three medicines: bempedoic acid, ezetimibe, and either rosuvastatin or atorvastatin. You might have started all three medicines at the same time, or bempedoic acid was added to your existing statin and ezetimibe, or ezetimibe was added to your existing statin and bempedoic acid.

There are also a few things that would mean you can't join. For example, if you've recently used certain other cholesterol-lowering treatments called PCSK9i monoclonal antibodies or ever used PCSK9i-siRNA, you wouldn't be eligible. Your doctor will carefully check if this study is right for you, making sure there are no reasons from your medical history that would prevent you from taking part.

This is an observational study, which means you won't be given any new drugs by the research team. You will continue to take the medicines your doctor has prescribed for your cholesterol (bempedoic acid, ezetimibe, and either rosuvastatin or atorvastatin) as part of your usual care. The study involves collecting information from your routine clinic visits and medical records over a period of one year. This will include your cholesterol levels, other blood test results, and any side effects you might experience. It also looks at how consistently you take your medicines. There will be specific checks at 8 weeks and again at 1 year from when you started the triple therapy.